Biogen Inc (BIIB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
160
About the Report
About the Report
Summary
Biogen Inc (Biogen) is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company's marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbryta (daclizumab), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several products candidates targeting various indications such as MS, Parkinson's disease, Alzheimer's disease and idiopathic pulmonary fibrosis, stroke, among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.
Biogen Inc (BIIB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Biogen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Biogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Biogen Inc, Medical Devices Deals, 2012 to YTD 2018 13
Biogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Biogen Inc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Biogen Acquires ALG-801 and ALG-802 from AliveGen 19
Biogen to Acquire TMS-007 Asset from TMS 20
Biogen Acquires CIAS Asset from Pfizer for up to USD590 Million 21
Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 22
Biogen Acquires CIRARA from Remedy Pharma 23
Biogen Idec Completes Acquisition Of Tysabri From Elan 24
Venture Financing 26
Solid Biosciences Raises USD50 Million in Series C Financing 26
Yumanity Therapeutics Raises USD45 Million in Series A Financing Round 28
Solid GT Raises USD42.5 Million in Series B Financing Round 30
True North Therapeutics Raises USD22 Million in Series A Venture Financing 31
Ataxion Raises USD 17 Million In Series A Financing 32
iPierian Raises USD 30 Million In Series A Venture Financing 33
Knopp Biosciences Raises USD 15 Million In First Tranche Of Venture Financing 35
Probiodrug Secures USD 19.5 Million In Series C Financing 36
Partnerships 38
Biogen Exercises Option Agreement with Neurimmune 38
Biogen and Ionis Pharma Enter into Agreement 39
Biogen and Ionis Pharma Enter into Agreement 40
Eisai Enters into Co-Promotion Agreement with Biogen 41
Biogen Enters into Partnership with Genomics 42
Ewopharma Enters into Distribution Agreement with Biogen 43
Siemens Healthcare Enters into Co-Development Agreement with Biogen 44
Amyris Enters into Agreement with Biogen 45
Biogen Enters into Co-Development Agreement with University of Pennsylvania 46
AC Immune Enters into Partnership with Biogen 47
Rodin Therapeutics Enters into R&D Agreement with Biogen 48
Arsia Therapeutics Enters into Research Agreement with Biogen 49
BioMotiv Expands its Agreement with Biogen 50
Renovo Neural Partners with Biogen 51
Biogen Enters into Agreement with Parkinson's Institute and Clinical Center 52
Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 53
Intec Pharma Enters into Research Agreement with Biogen MA 54
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Enter into Agreement to Develop Gene Therapies for Hemophilia 56
Biogen Idec Enters into Research Agreement with Columbia University Medical Center 57
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 58
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 59
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 60
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 61
White Head Institute And Biogen Idec Enter Into Reasearch Agreement 62
Eisai Expands Co-Development Agreement with Biogen 63
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 65
Biogen Idec Enters Into Co-Marketing Agreement With Samsung Bioepis To Commercialize Anti-TNF Biosimilar Product Candidates 66
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 67
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 68
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 69
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 70
Samsung Forms Joint Venture With Biogen Idec 72
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 73
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 74
Licensing Agreements 75
Biogen Enters into Licensing Agreement with Alkermes 75
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 76
Biogen Enters into Licensing Agreement with Forward Pharma 77
Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 79
Biogen Exercises Option for Licensing Agreement with Ionis Pharma 80
Biogen Enters into Licensing Agreement with RegenxBio 81
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 82
bluebird bio Enters into Licensing Agreement with Biogen 83
Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 84
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 85
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 86
MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 87
Biogen Idec Enters Into Licensing Agreement With Myelin Repair Foundation 88
Equity Offering 89
Bioverativ Spin Off from Biogen 89
Rodin Therapeutics to Raise USD17.3 Million in Private Placement of Preferred Stock 90
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 91
Debt Offering 93
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 93
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 95
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 97
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 99
Asset Transactions 101
Brammer Bio Acquires Cambridge Site from Biogen 101
Kiniksa Pharma Acquires Certain Assets Relating to KPL-716 from Biogen 102
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For USD 510 Million 104
DRI Capital Acquires Royalty Rights To Benlysta From Biogen Idec 105
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For USD 761 Million 106
Acquisition 107
Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 107
Biogen Idec Acquires Convergence Pharma for up to USD650.1 Million 108
Bristol-Myers Rumored To Acquire Biogen Idec 109
Biogen Idec Completes Acquisition Of Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 110
Takeda Completes Acquisition Of Intellikine For USD 310 Million 112
Biogen Inc-Key Competitors 114
Biogen Inc-Key Employees 115
Biogen Inc-Locations And Subsidiaries 117
Head Office 117
Other Locations & Subsidiaries 117
Joint Venture 121
Recent Developments 122
Financial Announcements 122
Jul 24, 2018: Biogen Q2 2018 revenues increase 9% tO USD 3.4 122
Jan 25, 2018: Biogen Reports Revenues for Both the Full Year and Fourth Quarter of 2017 125
Oct 24, 2017: Biogen Reports Quarterly Revenues of USD 3.1 Billion 128
Jul 25, 2017: Biogen Reports Record Quarterly Revenues of USD 3.1 Billion, Raises Full Year Revenue Guidance 130
Apr 25, 2017: Biogen Reports First Quarter 2017 Revenues of USD 2.8 Billion 133
Jan 26, 2017: Biogen Reports 2016 Revenues of USD 11.4 Billion 135
Corporate Communications 137
Dec 04, 2017: Biogen Appoints Mark Hernon as SVP, Chief Information Officer 137
Nov 21, 2017: Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer 138
Sep 25, 2017: Biogen Appoints Camille Lee as SVP, Alzheimer's Disease Therapeutic Area 139
Sep 12, 2017: Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical 140
Jun 20, 2017: Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer 141
Jun 14, 2017: Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations 142
Jun 13, 2017: Biogen Announces Management Change 143
Mar 16, 2017: Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development 144
Feb 01, 2017: Biogen Completes Separation of Global Hemophilia Business, Bioverativ 145
Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock 146
Legal and Regulatory 147
Aug 23, 2018: SEC Charges Former Pharma Executive and Others with Insider Trading 147
Sep 05, 2017: Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit 148
May 01, 2017: Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement 149
Feb 09, 2017: Forward Pharma Received USD 1.25bn pursuant to Settlement and License Agreement with Biogen 150
Government and Public Interest 151
Jun 18, 2018: Biogen Foundation Selects Grantees to Receive USD 10 Million Investment for STEM Education 151
May 27, 2018: Specialists in multiple sclerosis discuss the real world of patients 152
Product News 153
03/28/2017: Biogen to Present Data on BIIB054 at the 13th International Conference on Alzheimer's and Parkinson's Diseases 153
02/09/2017: Karyopharm and Collaborators Awarded Grant for ALS Drug Development 154
Product Approvals 155
Jan 16, 2017: Remedy Pharmaceuticals CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke 155
Clinical Trials 156
Oct 27, 2017: Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis 156
Oct 16, 2017: Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting 157
Mar 16, 2017: Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis 158
Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 159
Appendix 160
Methodology 160
About GlobalData 160
Contact Us 160
Disclaimer 160
List of Figure
List of Figures
Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Biogen Inc, Medical Devices Deals, 2012 to YTD 2018 13
List of Table
List of Tables
Biogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Biogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Biogen Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Biogen Inc, Medical Devices Deals, 2012 to YTD 2018 13
Biogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Biogen Acquires ALG-801 and ALG-802 from AliveGen 19
Biogen to Acquire TMS-007 Asset from TMS 20
Biogen Acquires CIAS Asset from Pfizer for up to USD590 Million 21
Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 22
Biogen Acquires CIRARA from Remedy Pharma 23
Biogen Idec Completes Acquisition Of Tysabri From Elan 24
Solid Biosciences Raises USD50 Million in Series C Financing 26
Yumanity Therapeutics Raises USD45 Million in Series A Financing Round 28
Solid GT Raises USD42.5 Million in Series B Financing Round 30
True North Therapeutics Raises USD22 Million in Series A Venture Financing 31
Ataxion Raises USD 17 Million In Series A Financing 32
iPierian Raises USD 30 Million In Series A Venture Financing 33
Knopp Biosciences Raises USD 15 Million In First Tranche Of Venture Financing 35
Probiodrug Secures USD 19.5 Million In Series C Financing 36
Biogen Exercises Option Agreement with Neurimmune 38
Biogen and Ionis Pharma Enter into Agreement 39
Biogen and Ionis Pharma Enter into Agreement 40
Eisai Enters into Co-Promotion Agreement with Biogen 41
Biogen Enters into Partnership with Genomics 42
Ewopharma Enters into Distribution Agreement with Biogen 43
Siemens Healthcare Enters into Co-Development Agreement with Biogen 44
Amyris Enters into Agreement with Biogen 45
Biogen Enters into Co-Development Agreement with University of Pennsylvania 46
AC Immune Enters into Partnership with Biogen 47
Rodin Therapeutics Enters into R&D Agreement with Biogen 48
Arsia Therapeutics Enters into Research Agreement with Biogen 49
BioMotiv Expands its Agreement with Biogen 50
Renovo Neural Partners with Biogen 51
Biogen Enters into Agreement with Parkinson's Institute and Clinical Center 52
Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 53
Intec Pharma Enters into Research Agreement with Biogen MA 54
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Enter into Agreement to Develop Gene Therapies for Hemophilia 56
Biogen Idec Enters into Research Agreement with Columbia University Medical Center 57
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 58
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 59
Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 60
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 61
White Head Institute And Biogen Idec Enter Into Reasearch Agreement 62
Eisai Expands Co-Development Agreement with Biogen 63
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 65
Biogen Idec Enters Into Co-Marketing Agreement With Samsung Bioepis To Commercialize Anti-TNF Biosimilar Product Candidates 66
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 67
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 68
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 69
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 70
Samsung Forms Joint Venture With Biogen Idec 72
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 73
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 74
Biogen Enters into Licensing Agreement with Alkermes 75
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 76
Biogen Enters into Licensing Agreement with Forward Pharma 77
Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 79
Biogen Exercises Option for Licensing Agreement with Ionis Pharma 80
Biogen Enters into Licensing Agreement with RegenxBio 81
Biogen Enters into Licensing Agreement with Applied Genetic Technologies 82
bluebird bio Enters into Licensing Agreement with Biogen 83
Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 84
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 85
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 86
MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 87
Biogen Idec Enters Into Licensing Agreement With Myelin Repair Foundation 88
Bioverativ Spin Off from Biogen 89
Rodin Therapeutics to Raise USD17.3 Million in Private Placement of Preferred Stock 90
Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 91
Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 93
Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 95
Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 97
Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 99
Brammer Bio Acquires Cambridge Site from Biogen 101
Kiniksa Pharma Acquires Certain Assets Relating to KPL-716 from Biogen 102
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For USD 510 Million 104
DRI Capital Acquires Royalty Rights To Benlysta From Biogen Idec 105
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For USD 761 Million 106
Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 107
Biogen Idec Acquires Convergence Pharma for up to USD650.1 Million 108
Bristol-Myers Rumored To Acquire Biogen Idec 109
Biogen Idec Completes Acquisition Of Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 110
Takeda Completes Acquisition Of Intellikine For USD 310 Million 112
Biogen Inc, Key Competitors 114
Biogen Inc, Key Employees 115
Biogen Inc, Other Locations 117
Biogen Inc, Subsidiaries 117
Biogen Inc, Joint Venture 121
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.